hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
== Serious and chronic complications == The serious complications of HiB are brain damage, hearing loss, and even death. While non-typable H. influenzae strains rarely cause serious disease, they are more likely to cause chronic infections because they have the ability to change their surface antigens. Chronic infections are usually not as serious as acute infections. There are a few other possible diseases and conditions that can arise from the H. influenzae depending on the areas that they exist in within the human body. This bacterium can exist in the nasal passages (especially the nasopharynx), the ear canal, and the lungs. The bacterium's presence in these areas can lead to some conditions such as otitis media, chronic obstructive pulmonary disorder (COPD), epiglottitis, and asthma which can become severe.
Genetic studies on the Sinhalese are part of population genetics investigating the ancestral origins of the Sinhalese people. A 2025 study utilizing whole genome sequencing has shown that the Sinhalese exhibit a close genetic proximity to South Indian populations and other groups within Sri Lanka, such as Sri Lankan Tamils and the Vedda. Modern genomic analysis suggests that the genetic contribution from Western Indian (Maratha) sources is more predominant than that from North Indian populations, though shared ancestral components exist across the broader South Asian subcontinent.
Chuang, R.S., Jaffe, H., Cribbs, L., Perez-Reyes, E., Swartz, K.J. (1998). Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nature Neuroscience 1(8), 668–674. [1] Sidach, S.S., Mintz, I.M. (2002). Kurtoxin, a gating modifier of neuronal high- and low threshold Ca channels. The Journal of Neuroscience, 22(6), 2023–2034. [2]
in vitro (of a scientific experiment or biological process) Occurring or made to occur in a laboratory vessel or other controlled artificial environment, e.g. in a test tube or a petri dish, as opposed to inside a living organism or in a natural setting.
Kissinger suggested another meeting with Tho in Paris, only to receive a note reading: "The U.S. words of peace are just empty ones". Kissinger's deputy, Haig, went to Phnom Penh to meet Lon Nol, who complained the invasion had not helped as it had only pushed the North Vietnamese and the Viet Cong deeper into Cambodia. In June 1970, the Americans pulled out of Cambodia, and the Vietnamese Communists returned, though the loss of weapons greatly hindered their operations in the Saigon area for the rest of 1970. Having committed itself to supporting Lon Nol, the United States now had two allies instead of one to support in Southeast Asia. The bombing campaign in Cambodia contributed to the chaos of the Cambodian Civil War, which saw the forces of leader Lon Nol unable to retain foreign support to combat the growing Khmer Rouge insurgency that would overthrow him in 1975. Documents uncovered from the Soviet archives after 1991 reveal that the North Vietnamese invasion of Cambodia in 1970 was launched at the explicit request of the Khmer Rouge and negotiated by Pol Pot's then second in command, Nuon Chea. The American bombing of Cambodia resulted in 40,000–150,000 deaths from 1969 to 1973, including at least 5,000 civilians. Pol Pot biographer David P. Chandler argues that the bombing "had the effect the Americans wanted—it broke the Communist encirclement of Phnom Penh".
Sources: en.wikipedia.org
In the 1700s, ivory dentures were developed from walrus, elephant or hippopotamus tusks. Alexis Duchateu crafted the first porcelain dentures in 1770. These were prone to cracking and appeared too white to be natural teeth. Duchateus was a pharmacist, since Denturist, as an occupation was yet to be established. In the 1800s, the incidence of dental decay and tooth loss began to increase rapidly. The industrialisation period meant the consumption of sugar among British citizens increased by 500 percent. A need for an alternative form of dentures was needed. In 1815, the Battle of Waterloo gave rise to the highly demanded "Waterloo teeth". These were dentures crafted primarily from the teeth of dead soldiers seated in a base of animal ivory. Waterloo dentures gave the appearance of natural teeth and were not as prone to breakage as porcelain dentures. In 1820, Claudius Ash was given the task of crafting a new and improved form of dentures. Ash was a silversmith and goldsmith. He constructed porcelain on 18-karat gold plates. The springs that held the dentures together were also made of gold. Dentures that were previously made from natural teeth or porcelain were both aesthetically and functionally inferior in comparison to Ash's design. In the 1850s, Ash and his company developed Vulcanite (hardened rubber that seated porcelain teeth). His company was the leading supplier of this form of dentures in Europe. Charles Goodyear was awarded the patent for Vulcanite-based dentures in 1851. Dentures, at the time, were primarily focused on aesthetics.
=== Common names === There are many common names for S. divinorum, including sage of the diviners, ska maría pastora, seer's sage, yerba de la pastora, simply salvia, and colloquially sally-d and magic mint.
== Assembly methods == A persistent problem within tissue engineering is mass transport limitations. Engineered tissues generally lack an initial blood supply, thus making it difficult for any implanted cells to obtain sufficient oxygen and nutrients to survive, or function properly.
==== Personality ==== Almost all Culture citizens are very sociable and of great intellectual capability and learning, and possess very well‑balanced psyches. Their biological make-up and their growing up in an enlightened society make neuroses and lesser emotions like greed or (strong) jealousy practically unknown, and produce persons that, in any lesser society, appear very self-composed and charismatic. Character traits like strong shyness, while very rare, are not fully unknown, as shown in Excession. As described there and in Player of Games, a Culture citizen who becomes dysfunctional enough to pose a serious nuisance or threat to others would be offered (voluntary) psychological adjustment therapy and might potentially find themself under constant (non-voluntary) oversight by representatives of the local Mind. In extreme cases, as described in Use of Weapons and Surface Detail, dangerous individuals have been known to be assigned a "slap-drone", a robotic follower who ensures that the person in question doesn't continue to endanger the safety of others.
Critics argue these programs are ineffective at preventing fatalities and advocate for alternatives such as helicopter patrols, acoustic tagging, and real-time social media tracking. While Western Australia implemented a cull in 2013, it was discontinued the following year following a recommendation from the state's Environmental Protection Authority. In April 2007, white sharks were given full protection within New Zealand waters 370 km (230 mi) from land, and from New Zealand-flagged vessels operating internationally. Violations carry penalties of up to a $250,000 fine and six months' imprisonment. In June 2018 the New Zealand Department of Conservation classified the white shark under the New Zealand Threat Classification System as "Nationally Endangered" due to its small, stable of between 250–1000 mature individuals. This classification carries the qualifiers "Data Poor", "Threatened Overseas", and "Conservation Dependent".
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.